Back to Journals » Vascular Health and Risk Management » Volume 7

Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience

Authors Hikmat N Abdel-Razeq, Asem H Mansour, Yousef M Ismael

Published 15 March 2011 Volume 2011:7 Pages 153—158

DOI https://doi.org/10.2147/VHRM.S17947

Review by Single-blind

Peer reviewer comments 3

Hikmat N Abdel-Razeq1, Asem H Mansour2, Yousef M Ismael1
1
Department of Internal Medicine, 2Department of Radiology, King Hussein Cancer Center, Amman, Jordan

Background and objectives: Cancer patients undergo routine imaging studies much more than others. The widespread use of the recently introduced multi-detector CT scanners has resulted in an increasing number of incidentally diagnosed pulmonary embolism (PE) in asymptomatic cancer patients. The significance and clinical outcome of such incidental PE is described.
Methods: Both radiology department and hospital databases were searched for all cancer patients with a diagnosis of incidental PE. CT scans were performed using a 64-slice scanner with a 5.0 mm slice thickness.
Results: During the study period, 34 patients with incidental PE were identified. The mean age (±SD) was 57.7 (±12.4) years. All patients had active cancer, gastric, lung, colorectal, and lymphomas being the most frequent. Most patients had advanced-stage disease at the time of PE diagnosis; 26 (77%) patients had stage IV, whereas only 3 patients had stages I or II disease. Twenty-seven (79%) patients had their PE while undergoing active treatment with chemotherapy (68%) or radiotherapy (12%); none, however, were on hormonal therapy. Most (74%) patients had their PE diagnosed without history of recent hospital admission. Except for 5 (15%), all other patients were anticoagulated. With follow-up, 2 patients developed recurrent PE, 2 others had clinical and echocardiographic evidence of pulmonary hypertension, and 9 (26%) died suddenly within 30 days of the diagnosis of incidental PE; 2 of these where among the 5 patients who were not anticoagulated.
Conclusion: Incidental PE in cancer patients is increasingly encountered. Similar to symptomatic PE, many were diagnosed in patients with advanced stage disease and while undergoing active anti-cancer therapy. A significant percentage of patients had recurrent emboli, pulmonary hypertension, and sudden death.
Keywords: pulmonary embolism, incidental, cancer, chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience

Mansour A, Ismael Y, Abunasser M, Hammode E, Turfa R, Abdel-Razeq H

Patient Preference and Adherence 2013, 7:1111-1116

Published Date: 23 October 2013

Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study

Abdel-Razeq H, Abbasi S, Saadi I, Jaber R , Abdulelah H

Drug Design, Development and Therapy 2013, 7:939-944

Published Date: 30 August 2013

Current neoadjuvant treatment options for HER2 positive breast cancer

Abdel-Razeq H, Marei L

Biologics: Targets and Therapy 2011, 5:87-94

Published Date: 9 August 2011

Inferior vena cava filters in cancer patients: to filter or not to filter

Hikmat Abdel-Razeq, Asem Mansour, Yousef Ismael, et al

Therapeutics and Clinical Risk Management 2011, 7:99-102

Published Date: 10 March 2011

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Advances in cancer pain from bone metastasis

Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY

Drug Design, Development and Therapy 2015, 9:4239-4245

Published Date: 18 August 2015

Clinical epidemiology of epithelial ovarian cancer in the UK

Doufekas K, Olaitan A

International Journal of Women's Health 2014, 6:537-545

Published Date: 23 May 2014

Focal low-dose rate brachytherapy for the treatment of prostate cancer

Tong WY, Cohen G, Yamada Y

Cancer Management and Research 2013, 5:315-325

Published Date: 13 September 2013

How to reduce your cancer risk: mechanisms and myths

Nahleh Z, Bhatti NS, Mal M

International Journal of General Medicine 2011, 4:277-287

Published Date: 8 April 2011

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011